Granules India gains after receiving US FDA nod for gout medicine

Attention Investors

Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000. | Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors." | KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary." | ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

- EQUITY
  EQUITY
  PRICE
  
  Gainers & Losers
  
  Advances & Declines
  
  New Highs & Lows
  
  Index Movers
  
  Only Buyers/Sellers
  
  Out/Under Performers
- NEWS
  CORPORATE ACTIONS
  
  Announcements
  
  Book Closure
  
  Board Meetings
  
  Bonus Issues
  
  Rights Issues
  
  De-Listed Shares
  
  Market Turnover
  
  Change of Name
  
  Split of Face Value
- OTHER MARKETS
  FII Investments
  
  MF Investments
  
  ADR Prices
  
  World Indices
  
  Forex
  
  CORPORATE INFO
- VOLUME
  VOLUME
  Value & Volume Toppers
  
  Unusual Volume
  
  Bulk & Block Deals
  
  Sector Watch
- ANALYSIS
  ANALYSIS
  52 Week High Low
  
  Live Indices
  
  Exchange Holidays
  
  Index Constituents
  
  Historical Returns
  
  Circuit Breakers
- IPO
  IPO
  
  Forthcoming Issues
  
  Open Issues
  
  Closed Issues
  
  New Listing
  
  Basis of Allotment
  
  Draft Prospectus
  
  New Issue Monitor
  
  Best Performers
  
  Know IPO's / FAQ's

Saturday, May 18, 2024

Asian Paints

2816.55

(0.24%)

Axis Bank

1143.15

(0.15%)

Bajaj Finance

6735.05

(0.10%)

Bajaj Finserv

1586.30

(0.11%)

Bharti Airtel

1348.20

(0.30%)

HCL Technologi..

1338.65

(0.43%)

HDFC Bank

1465.40

(0.03%)

Hind. Unilever

2327.40

(0.34%)

ICICI Bank

1130.15

(-0.03%)

IndusInd Bank

1417.65

(0.42%)

Infosys

1443.75

(-0.02%)

ITC

436.45

(-0.03%)

JSW Steel

891.00

(-1.80%)

Kotak Mah. Ban..

1696.40

(-0.04%)

Larsen & Toubr..

3464.25

(0.41%)

M & M

2504.30

(-0.40%)

Maruti Suzuki

12603.35

(-0.32%)

Nestle India

2502.20

(2.33%)

NTPC

366.40

(0.27%)

Power Grid Cor..

316.85

(1.12%)

Reliance Indus..

2869.05

(-0.06%)

St Bk of India

820.85

(0.37%)

Sun Pharma.Ind..

1530.80

(-0.05%)

Tata Motors

952.95

(0.76%)

Tata Steel

167.90

(0.39%)

TCS

3850.00

(0.42%)

Tech Mahindra

1305.50

(0.05%)

Titan Company

3360.80

(-0.02%)

UltraTech Cem.

9860.80

(-0.30%)

Wipro

462.35

(0.28%)

	Equity Analysis

	News Analysis

	Corporate Actions

	Other Market

	Company Profile

Share Holding Pattern

Your results on : Equity | News | Company-News

Granules India gains after receiving US FDA nod for gout medicine	Share Back
(30 Apr 2024)
The ANDA for Colchicine Capsules was filed by the company’s wholly owned foreign subsidiary Granules Pharmaceuticals, Inc. (GPI). The approved drug is a bioequivalent and therapeutically equivalent to the reference listed drug (RLD) Mitigare Capsules of Hikma International Pharmaceuticals LLC (Hikma). Colchicine Capsules are indicated for prophylaxis of gout flares in adults. The current annual U.S. market for Colchicine Capsules is approximately $55 Million, according to MAT Feb 2024, IQVIA/IMS Health. 'Granules now have a total of 64 ANDA approvals from the US FDA (63 Final approvals and 1 tentative approvals),” the company said in a statement. Granules India is primarily involved in the manufacturing and selling of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation intermediates (PFIs) and Finished Dosages (FDs). The pharma company's consolidated net profit rose 1.06% to Rs 125.65 crore on 0.82% increase in revenue from operations to Rs 1,155.58 crore in Q3 FY24 over Q3 FY23.
Top